Effects of IL-1β, TNF-α, and macrophage migration inhibitory factor on prostacyclin synthesis in rat pulmonary artery smooth muscle cells

被引:50
作者
Itoh, A
Nishihira, J
Makita, H
Miyamoto, K
Yamaguchi, E
Nishimura, M
机构
[1] Hokkaido Univ, Sch Med, Dept Med 1, Sapporo, Hokkaido 060, Japan
[2] Cent Res Inst, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ, Coll Med Technol, Dept Phys Therapy, Sapporo, Hokkaido 060, Japan
关键词
interleukin-1; macrophage migration inhibitory factor; prostaglandins; pulmonary artery; tumour necrosis factor-alpha;
D O I
10.1046/j.1440-1843.2003.00491.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objective: Cytokines have been implicated in the pathophysiology of pulmonary hypertension. We sought to explore the possibility that prostacyclin is a link. Methodology: We tested the effects of the cytokines interleukin-1beta (IL-1beta), tumour necrosis factor-alpha (TNF-alpha), and macrophage migration inhibitory factor (MIF) on arachidonic acid metabolism of pulmonary artery smooth muscle cells (PASMCs) with special regard to prostacyclin (PGI(2)) that protects against pulmonary hypertension. Cultured rat PASMCs were treated with IL-1beta, TNF-alpha, or MIF. Expression of prostacyclin synthase (PGIS) and cyclooxygenase-2 (COX-2) mRNAs, and PGI(2) synthesis, were measured. Results: We found that PGIS mRNA expression was suppressed by high concentrations of TNF-alpha and MIF, while COX-2 mRNA was induced by all three cytokines tested. IL-1beta increased PGI(2) production in a dose-dependent manner. TNF-alpha and MIF also increased PGI(2) production, but to a far lesser degree at high concentrations. TNF-alpha. paradoxically decreased PGI(2) production at a low concentration. Conclusions: These results suggest that TNF-alpha and MIF are potentially antagonistic to the action of PGI(2) in rat PASMCs via down-regulation of PGIS mRNA. Simultaneous induction of COX-2 mRNA may further counteract the action of PGI(2) by increasing the levels of eicosanoids other than PGI(2).
引用
收藏
页码:467 / 472
页数:6
相关论文
共 30 条
[1]  
Ausubel FM., 1998, CURRENT PROTOCOLS MO
[2]   Regulation and inhibition of phospholipase A2 [J].
Balsinde, J ;
Balboa, MA ;
Insel, PA ;
Dennis, EA .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :175-189
[3]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[4]  
Belton O, 2000, CIRCULATION, V102, P840
[5]   Transcellular formation of thromboxane A2 in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin I-synthase activity [J].
Camacho, M ;
Vila, L .
THROMBOSIS RESEARCH, 2000, 99 (02) :155-164
[6]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[7]  
Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650
[8]   ANALYSIS OF PROSTACYCLIN AND THROMBOXANE BIOSYNTHESIS IN CARDIOVASCULAR-DISEASE [J].
FITZGERALD, GA ;
PEDERSEN, AK ;
PATRONO, C .
CIRCULATION, 1983, 67 (06) :1174-1177
[9]   Overexpression of tumor necrosis factor-α produces an increase in lung volumes and pulmonary hypertension [J].
Fujita, M ;
Shannon, JM ;
Irvin, CG ;
Fagan, KA ;
Cool, C ;
Augustin, A ;
Mason, RJ .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2001, 280 (01) :L39-L49
[10]   Pulmonary prostacyclin, synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension [J].
Geraci, MW ;
Gao, BF ;
Shepherd, DC ;
Moore, MD ;
Westcott, JY ;
Fagan, KA ;
Alger, LA ;
Tuder, RM ;
Voelkel, NF .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (11) :1509-1515